Boxu Yan

Summary

Affiliation: Amgen Inc
Country: USA

Publications

  1. ncbi Analysis of human antibody IgG2 domains by reversed-phase liquid chromatography and mass spectrometry
    Boxu Yan
    Department of Analytical and Formulation Science, Amgen Inc, 1201 Amgen Court West, Seattle, WA 98119, USA
    J Chromatogr B Analyt Technol Biomed Life Sci 877:1613-20. 2009
  2. ncbi Human IgG1 hinge fragmentation as the result of H2O2-mediated radical cleavage
    Boxu Yan
    Department of Analytical and Formulation Science, Amgen Incorporated, Seattle, Washington 98119, USA
    J Biol Chem 284:35390-402. 2009
  3. ncbi Analysis of post-translational modifications in recombinant monoclonal antibody IgG1 by reversed-phase liquid chromatography/mass spectrometry
    Boxu Yan
    Department of Analytical Science, Amgen Inc, Seattle, WA 98119, USA
    J Chromatogr A 1164:153-61. 2007
  4. ncbi Succinimide formation at Asn 55 in the complementarity determining region of a recombinant monoclonal antibody IgG1 heavy chain
    Boxu Yan
    Department of Analytical and Formulation Science, Amgen Inc, 1201 Amgen Court West, Seattle, Washington 98119, USA
    J Pharm Sci 98:3509-21. 2009
  5. ncbi Asparagine-linked oligosaccharides present on a non-consensus amino acid sequence in the CH1 domain of human antibodies
    John F Valliere-Douglass
    Department of Process and Product Development, Amgen Inc, Seattle, Washington 98119 3105, USA
    J Biol Chem 284:32493-506. 2009
  6. ncbi Investigation of degradation processes in IgG1 monoclonal antibodies by limited proteolysis coupled with weak cation-exchange HPLC
    Hollis Lau
    Department of Analytical and Formulation Sciences, Amgen Inc, 1201 Amgen Court West, Seattle, WA 98119 3105, USA
    J Chromatogr B Analyt Technol Biomed Life Sci 878:868-76. 2010
  7. ncbi Histidine residue mediates radical-induced hinge cleavage of human IgG1
    Zac Yates
    Department of Analytical and Formulation Science, Amgen Inc, Seattle, Washington 98119, USA
    J Biol Chem 285:18662-71. 2010
  8. ncbi O-fucosylation of an antibody light chain: characterization of a modification occurring on an IgG1 molecule
    John F Valliere-Douglass
    Department of Analytical and Formulation Sciences, Amgen, 1201 Amgen Court West, Seattle, WA 98119 3105, USA
    Glycobiology 19:144-52. 2009
  9. ncbi In vitro galactosylation of human IgG at 1 kg scale using recombinant galactosyltransferase
    Dale Warnock
    Neose Technologies, Inc, 102 Witmer Road, Horsham, Pennsylvania 19044, USA
    Biotechnol Bioeng 92:831-42. 2005
  10. ncbi S-nitrosylation of matrix metalloproteinases: signaling pathway to neuronal cell death
    Zezong Gu
    Center for Neuroscience and Aging, Program in Cell Adhesion and Extracellular Matrix Biology, The Burnham Institute, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA
    Science 297:1186-90. 2002

Collaborators

  • Ramil F Latypov
  • Zhi Liu
  • Kannan Gunasekaran
  • Stuart Lipton
  • John F Valliere-Douglass
  • Hollis Lau
  • Zac Yates
  • Danielle Pace
  • Alison Wallace
  • Michael J Treuheit
  • Alain Balland
  • Lowell J Brady
  • Jeffrey W Smith
  • Dale Warnock
  • David A Calderwood
  • Robert C Liddington
  • Zezong Gu
  • Jihea Park
  • Theresa McGrath
  • Zhonghua Hu
  • Hongxing Zhou
  • Scott Smallwood
  • Sungae S Park
  • Randal R Ketchem
  • Ketaki Patel
  • Wes Wang
  • Wesley Wang
  • Paul Kodama
  • Mirna Mujacic
  • Pranhitha Reddy
  • Chris Farnsworth
  • Jun Qian
  • David Zopf
  • Xiaomei Bai
  • Johnny Gonzales
  • Robert J Bayer
  • Tom Stevenson
  • Kyle Kinealy
  • Katie Autote
  • Christian R Lombardo
  • Begoña García Alvarez
  • Steven J Kridel
  • Alex Strongin
  • France Landry
  • Mark H Ginsberg
  • Jose M de Pereda
  • Marcus Kaul
  • Jiankun Cui
  • Yosuke Fujioka

Detail Information

Publications12

  1. ncbi Analysis of human antibody IgG2 domains by reversed-phase liquid chromatography and mass spectrometry
    Boxu Yan
    Department of Analytical and Formulation Science, Amgen Inc, 1201 Amgen Court West, Seattle, WA 98119, USA
    J Chromatogr B Analyt Technol Biomed Life Sci 877:1613-20. 2009
    ....
  2. ncbi Human IgG1 hinge fragmentation as the result of H2O2-mediated radical cleavage
    Boxu Yan
    Department of Analytical and Formulation Science, Amgen Incorporated, Seattle, Washington 98119, USA
    J Biol Chem 284:35390-402. 2009
    ..As a precursor of hydroxyl radicals, H(2)O(2) is widely produced in healthy cells and tissues and therefore could be the source for the radical-induced fragmentation of human IgG1 antibodies in vivo...
  3. ncbi Analysis of post-translational modifications in recombinant monoclonal antibody IgG1 by reversed-phase liquid chromatography/mass spectrometry
    Boxu Yan
    Department of Analytical Science, Amgen Inc, Seattle, WA 98119, USA
    J Chromatogr A 1164:153-61. 2007
    ..This study presents a strategy that offers orthogonal approaches to analyze antibody variants, and provide a qualitative and quantitative assessment of mAb heterogeneity...
  4. ncbi Succinimide formation at Asn 55 in the complementarity determining region of a recombinant monoclonal antibody IgG1 heavy chain
    Boxu Yan
    Department of Analytical and Formulation Science, Amgen Inc, 1201 Amgen Court West, Seattle, Washington 98119, USA
    J Pharm Sci 98:3509-21. 2009
    ..Hydrolysis of the succinimide resulted in a further drop in potency. The implications of the succinimide formation at Asn 55, a highly conserved residue among IgG1 (mAbs), are discussed...
  5. ncbi Asparagine-linked oligosaccharides present on a non-consensus amino acid sequence in the CH1 domain of human antibodies
    John F Valliere-Douglass
    Department of Process and Product Development, Amgen Inc, Seattle, Washington 98119 3105, USA
    J Biol Chem 284:32493-506. 2009
    ..We believe that further understanding of the phenomenon of non-consensus glycosylation can be used to gain fundamental insights into the fidelity of the cellular glycosylation machinery...
  6. ncbi Investigation of degradation processes in IgG1 monoclonal antibodies by limited proteolysis coupled with weak cation-exchange HPLC
    Hollis Lau
    Department of Analytical and Formulation Sciences, Amgen Inc, 1201 Amgen Court West, Seattle, WA 98119 3105, USA
    J Chromatogr B Analyt Technol Biomed Life Sci 878:868-76. 2010
    ..Overall, the data presented demonstrate the suitability of this cation-exchange HPLC method for studying a wide range of covalent and noncovalent degradations in IgG1 mAbs...
  7. ncbi Histidine residue mediates radical-induced hinge cleavage of human IgG1
    Zac Yates
    Department of Analytical and Formulation Science, Amgen Inc, Seattle, Washington 98119, USA
    J Biol Chem 285:18662-71. 2010
    ..The work presented here suggests the feasibility of engineering a new generation of monoclonal antibodies capable of resisting hinge cleavage to improve product stability and efficacy...
  8. ncbi O-fucosylation of an antibody light chain: characterization of a modification occurring on an IgG1 molecule
    John F Valliere-Douglass
    Department of Analytical and Formulation Sciences, Amgen, 1201 Amgen Court West, Seattle, WA 98119 3105, USA
    Glycobiology 19:144-52. 2009
    ....
  9. ncbi In vitro galactosylation of human IgG at 1 kg scale using recombinant galactosyltransferase
    Dale Warnock
    Neose Technologies, Inc, 102 Witmer Road, Horsham, Pennsylvania 19044, USA
    Biotechnol Bioeng 92:831-42. 2005
    ..Removal of glycosylation reagents from the product is achieved in one step by affinity chromatography on immobilized Protein A...
  10. ncbi S-nitrosylation of matrix metalloproteinases: signaling pathway to neuronal cell death
    Zezong Gu
    Center for Neuroscience and Aging, Program in Cell Adhesion and Extracellular Matrix Biology, The Burnham Institute, 10901 North Torrey Pines Road, La Jolla, CA 92037, USA
    Science 297:1186-90. 2002
    ..These findings suggest a potential extracellular proteolysis pathway to neuronal cell death in which S-nitrosylation activates MMPs, and further oxidation results in a stable posttranslational modification with pathological activity...
  11. ncbi Redox control of integrin adhesion receptors
    Jeffrey W Smith
    Cancer Research Center, Burnham Institute, La Jolla, California 92037, USA
    Methods Enzymol 353:156-63. 2002
  12. ncbi The phosphotyrosine binding-like domain of talin activates integrins
    David A Calderwood
    Division of Vascular Biology, Department of Cell Biology, The Scripps Research Institute, La Jolla, California 92037, USA
    J Biol Chem 277:21749-58. 2002
    ..These resemblances suggest that the activation of integrins requires the presence of a beta turn at NPX(Y/F) motifs conserved in integrin beta cytoplasmic domains...